Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 3Phase 2/3 2Phase 1/2 1Phase 1 1

Status

Completed 6Withdrawn 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 1

Interventions

Cyclophosphamide 118pembrolizumab 104Specimen Handling 104Magnetic Resonance Spectroscopy 94fludarabine 92Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 36Paclitaxel 35Carboplatin 35Cetuximab 34Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Leucovorin 28Gemcitabine 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20Doxorubicin 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Asparaginase × Clear all
NCT07133997 2026-04-07

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

City of Hope Medical Center

Phase 1 Recruiting
26 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡